Familial defective apolipoprotein B-100

Danish Medical Bulletin

Volumn 45, Issue 4, 1998, Pages 370-382

  Hansen, Peter Steen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

CHROMOSOME 19; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; FAMILIAL HYPERLIPEMIA; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOPROTEIN METABOLISM; REVIEW;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MUTATION; PEDIGREE; RATS;

EID: 0031706072     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Hansen PS, Rüdiger N, Tybjærg-Hansen A, Faergeman O, Gregersen N: Detection of the apoB-3,500 mutation (Glutamine for Arginine) by gene amplification and cleavage with Mspl. J Lipid Res 1991; 32: 1229-1233.
2. Nissen H, Hansen PS, Færgeman O, Hørder M: Mutation Screening of the Codon 3,500 Region of the Apolipoprotein B Gene by Denaturing Gradient-Gel Electrophoresis.
3. Hansen PS, Nørgaard-Petersen B, Meinertz H, Jensen HK, Hansen ABB, Klausen IC, Gerdes LU, Faergeman O: Incidence of the apolipoprotein B-3,500 mutation in Denmark. Clin Chim Ada 1994; 230: 101-104.
4. Hansen PS, Meinertz H, Jensen HK, Fruergaard P, Launbjerg J, Klausen IC, Lemming L, Gerdes LU, Gregersen N, Faergeman O: Characteristics of 46 heterozygous carriers and 57 unaffected relatives in 5 Danish families with familial defective apolipoprotein B-100. Arterioscler Thromb 1994; 14: 207-213.
5. Hansen PS, Defesche JC, Kastelein JJP, Gerdes LU, Fraza L, Gerdes C, Tato F, Jensen HK, Jensen LG, Klausen IC, Faergeman O, Schuster H: Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. Arterioscler Thromb Vase Biol 1997; 17: 741-747.
6. Hansen PS, Meinertz H, Gerdes LU, Klausen IC, Faergeman O: Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil; a two-period cross-over study. Clin Invest 1994; 72: 1065-1070.
7. Aalto-Setälä K, Tikkanen MJ, Taskinen MR, Nieminen M, Holmberg P, Kontula K: Xbal andc/g polymorphisms of the apolipoprotein B gene locus are associated with serum cholesterol and LDL-cholesterol levels in Finland. Atherosclerosis 1988; 74: 47-54.
8. Aalto-Setälä K, Helve E, Kovanen PT, Kontula K: Finnish type of low density lipoprotein receptor gene mutation (FH-Helsinki) deletes exons encoding the carboxyl-terminal part of the receptor and creates an internalization-defective phenotype. J Clin Invest 1989; 84: 499-505.
9. Ahn YI, Kamboh MI, Hamman RF, Cole SA, Ferrell RE: Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease. J Lipid Res 1993; 34: 421-428.
10. Ahn YI, Kamboh MI, Aston CE, Ferrell RE, Hamman RF: Role of common genetic polymorphisms in the LDL receptor gene in affecting plasma cholesterol levels in the general population. Arterioscler Thromb 1994; 14: 663-670.
11. Andersen LK, Jensen HK, Juul S, Færgeman O: Patients' attitudes to detection of heterozygous familial hypercholesterolemia. Arch Int Med 1997; 157: 553-560.
12. Appleyard M: The Copenhagen City Heart Study. Scand J Soc Med 1989; Suppl. 17.
13. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland Kreuzer H, Seidel D: The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986; 249: 257.
14. Arnold KS, Balestra ME, Krauss RM, Curtiss LK, Young SG, Innerarity TL: Isolation of allele-specific, receptor-binding-defective low density liporoteins from familial defective apolipoprotein B-100 subjects. J Lipid Res 1994; 35: 1469-1476.
15. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-1921.
16. Berg K: DNA polymorphism at the apolipoprotein B locus is associated with lipoprotein level. Clin Genet 1986; 30: 515-520.
17. Berg K: Level genes and variability genes in the etiology of hyperlipidemia and atherosclerosis, in Berg K, Retterstol N, Refsum S (eds): From phenotype to gene in common disorders. Copenhagen, Munksgaard A/S International Publishers, 1990, pp 77-91.
18. Bersot TP, Russell SJ, Thatcher SR, Pomernacki NK, Mahley RW, Weisgraber KH, Innerarity TL, Fox CS: A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during a study of the prevalence of this disorder. J Lipid Res 1993; 34: 1149-1154.
19. Billheimer DW, Grundy SM, Brown MS, Goldstein JL: Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoproteins from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983; 80: 4124-4128.
20. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
21. Brown WV, Howard WJ, Field L: Nicotinic acid and its derivatives, in Rifkind BM (ed): Drug treatment of hyperlipidemia. New York, Basel, Hong Kong, Marcel Dekker, Inc., 1991, pp 189-213.
22. Chen SH, Yang CY, Chen PF, Setzer D, Tanimura M, Li WH, Gotto AM, Chan L: The complete cDNA and amino acid sequence of human apolipoprotein B-100. J Biol Chem 1986; 28: 12918-12921.
23. Cladaras C, Hadzopoulou-Cladaras M, Nolte RT, Atkinson D, Zannis VI: The complete sequence and structural analysis of human apolipoprotein B-100: Relationship between apo B-100 and apo B-48 forms. EMBO J 1986; 5: 3495-3507.
24. Connor SL, Connor WE, Sexton G, Calvin L, Bacon S: The effects of age, body weight and family relationships on plasma lipoproteins and lipids in men, women and children of randomly selected families. Circulation 1982; 65: 1290-1298.
25. Coresh J, Kwiterowich PO, Smith HH, Bachorik PS: Association of plasma triglyceride concentrations and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 1993; 34: 1687-1697.
26. Corsini A, McCarthy BJ, Granata A, Soria LF, Fantappie S, Romano C, Romano L, Fumagalli R, Catapano AL: Familial defective apo B-100, characterization of an Italian family. Eur J Clin Invest 1991; 21: 389-397.
27. Dallongeville J, Lussier-Cacan C, Davignon J: Modulation of plasma triglyceride levels by apo E phenotype: a mela-analysis. J Lipid Res 1992; 33: 447-454.
28. Davey-Smith G, Shipley MJ, Marmot MG, Rose G: Plasma cholesterol and mortality: The Whitehall study. JAMA 1992; 267: 70-76.
29. Defesche JC, Pricker KL, Hayden MR, van der Ende BE, Kastelein JJP: Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Intern Med 1993; 153: 2349-2356.
30. Durovic S, März W, Frank S, Scharnagl H, Baumstark MW, Zechner R, Kostner GM: Decreased binding of apolipoprotein(a) to familial defective apolipoprotein B-100 (Arg3500-Gln). J Biol Chem 1994; 269: 30320-30325.
31. Durrington PN, Hunt L, Ishola M, Kane J, Stephens WP: Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J 1986; 56: 206-212.
32. Eggertsen G, Eriksson M, Wiklund O, litiä A, Olofsson SO, Angelin B, Berglund L: Time-resolved fluorometri in the genetic diagnosis of familial defective apolipoprotein B-100. J Lipid Res 1994; 35: 1505-1508.
33. Endo A: The discovery and development of HMG-coA reductase inhibitors. J Lipid Res 1992; 33: 1569-1582.
34. Ferneres J, Sing CF, Roy M, Davignon J, Lussier-Cacan S: Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: sex-specific effects. Arterioscler Thromb 1994; 14: 1553-1560.
35. Friedl W, Ludwig EH, Balestra ME, Arnold KS, Paulweber B, Sandhofer F, McCarthy BJ, Innerarity TL: Apolipoprotein B gene mutations in Austrian subjects with heart disease and their kindred. Arterioscler Thromb 1991; 11: 371-378.
36. Friedlander Y, Dann EJ, Leitersdorf E: Ascence of familial defective apolipoprotein B-100 in Israeli patients with dominantly inherited hypercholesterolemia and in offspring with parental history of myocardial infarction. Hum Genet 1993; 91: 299-300.
37. Frostegaard J, Hamsten A, Gidlund M, Nilsson J: Low density lipoprotein-induce growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein. J Lipid Res 1990; 31: 37-44.
38. Funke H, Rust S, Seedorf U, Brennhausen B, Chirazi A, Motti C, Assmann G; Homozygosity for familial defective apolipoprotein B-100 (FDB) is associated with lower plasma cholesterol concentrations than homozygosity for familial hypercholesterolemia. Circulation 1992; 86(suppl.I): 1-691. Abstract.
39. Gaffney D, Reid JM, Cameron IM, Vass K, Caslake MJ, Shepherd J, Packard CJ; Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vase Biol 1995; 15: 1025-1029.
40. Gallagher JJ, Myant NB: The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100. Atherosclerosis 1995; 115: 263-272.
41. Geisel J, Schleifenbaum T, Weisshaar B, Oette K: Rapid diagnosis of familial defective apolipoprotein B-100. Eur J Clin Chem Clin Biochem 1991; 29: 395-399.
42. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG: A molecular basis for familial hypertrophic cardiomyopathy: a beta-cardiac myosin heavy chain gene missense mutation. Cell 1990; 62: 999-1006.
43. Genest JJ, Martin-Munley SS, McNamara J: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85: 2025-2033.
44. Gerdes C, Gerdes LU, Hansen PS, Faergeman O: Polymorphism in the lipoprotein lipase gene and their association with plasma lipid concentrations in 40 years old Danish men. Circulation 1995; 92: 1765-1769.
45. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG: Hyperlipidemia in coronary heart disease. III. Genetic analysis of lipid levels in 176 families and deliniation of a new, inherited disorder, combined. hyperlipidemia. J Clin Invest 1973; 52: 1544-1568.
46. Goldstein JL, Brown MS: Familial hypercholesterolemia, in Schriver CR, Beaudet AL, Sly WS (eds): The Metabolic Basis of Inherited Disease. New York, McGraw-Hill, 1989, pp 1215-1250.
47. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J: Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-253.
48. Grundy SM: HMG CoA Reductase Inhibitors: Clinical applications and therapeutic potential, in Rifkind BM (ed): Drug treatment of hyperlipidemia. New York, Basel, Hong Kong, Marcel Dekker, Inc., 1991, pp 139-167.
49. Hämäläinen T, Palotie A, Aalto-Setälä K, Kontula K, Tikkanen MJ: Absence of familial defective apolipoprotein B-100 in Finnish patients with elevated serum cholesterol. Atheroslerosis 1990; 82: 177-183.
50. Hansen PS, Gerdes LU, Klausen IC, Gregersen N, Faergeman O: Polymorphism in the apolipoprotein B-100 gene contributes to normal variation in plasma lipids in 464 Danish men born in 1948. Hum Genet 1993; 91: 45-50.
51. Hansen PS, Klausen IC, Lemming L, Gerdes LU, Gregersen N, Faergeman O: Apolipoprotein B gene polymorphisms in ischemie heart disease and hypercholesterolemia: effects of age and sex, Clin Genet 1994; 45: 78-83.
52. Heath F, Jensen TG, Hansen PS, Jensen LG, Vissinger H, Moestrup SK, Pedersen S, Kølvraa S, Bolund L, Faergeman O: A flow cytometric competition technique for measuring interaction of LDL with cellular LDL-receptors applied to patients with mutant (Arg3500-GIn) apolipoprotein B. Z Gastroenterol 1996; 34: 21-24.
53. Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G, Jacobs D, Frantz ID: Lipoprotein cholesterol distribution in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1980; 61: 302-315.
54. Hobbs HH, Brown MS, Russell DW, Davignon J, Goldstein JL: Deletion in the gene for the low density lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987; 317: 734-737.
55. Hobbs HH, Brown MS, Goldstein JL: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445-466.
56. Humphries S, Coviello DA, Masturzo P, Balestreri R, Orecchini G, Bertolini S: Variation in the low density lipoprotein receptor gene is associated with differences in plasma low density lipoprotein cholesterol levels in young and old normal individuals from Italy. Arterioscler Thromb 1991; 11: 509-516.
57. Hunninghake DB: Bile acid sequestrants, in Rifkind BM (ed): Drug treatment of hyperlipidemia. New York, Basel, Hong Kong, Marcel Dekker,Inc., 1991, pp 89-102.
58. Illingworth DR: Fibric acid derivatives, in Rifkind BM (ed): Drug treatment of hyperlipidemia. New York, Basel, Hong Kong, Marcel Dekker, Inc., 1991, pp 103-138.
59. Illingworth DR, Vakar F, Mahley RW, Weisgraber KH: Hypocholesterolemic effects of lovastatin in familial defective apolipoprotein B-100. Lancet 1992; 339: 598-600.
60. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM: Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987; 84: 6919-6923.
61. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ: Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31: 1337-1349.
62. Innerarity TL, Balestra ME, Zhao Y, Arnold KS, Yao Z: Demonstration that the Arg3500-Gln mutation is the cause of familial defective apolipoprotein B-100, using a cell culture expression system for the synthesis of recombinant human LDL. Circulation 1993; 88: 1-322.
63. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-3012.
64. Klausen IC, Gerdes LU, Meinertz H, Hansen FA, Faergeman O: Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolemia treated with bile acid sequestration. Eur J Clin Invest 1993; 23: 240-245.
65. Knott TJ, Pease RJ, Powell LM, Wallis SC, Rall SC, Innerarity TL, Blackhart B, Taylor WH, Marcel Y, Milne R, Johnson D, Fuller M, Lusis AJ, McCarthy BJ, Mahley RW, Levy-Wilson B, Scott J: Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature 1986; 323: 734-738.
66. Kotze MJ, Langenhoven E, Warnich L, du Plessis L, Retief AE: The molecular basis and diagnosis of familial hypercholesterolemia in South African Afrikaners. Ann Hum Genet 1991; 55: 115-121.
67. Kotze MJ, Langenhoven E, Peeters AV, Theart L, Oosthuizen CJJ: Detection of two point mutations causing familial defective apolipoprotein B-100 by heteroduplex analysis. Mol Cell Probes 1994; 8: 513-518.
68. Kotze MJ, Peeters AV, Langenhoven E, Wauters JG, van Gaal LF: Phenotypic expression and frequency of familial defective apolipoprotein B-100 in Belgian hypercholesterolemics. Atheroslerosis 1994; 111: 217-225.
69. Krempler F, Kostner GM, Roscher A, Haslauer F, Bolzano K, Sandhofer F: Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 1983; 71: 1431-1441.
70. Law SW, Lee N, Monge JC, Brewer HB Jr, Sakaguchi AY, Naylor SL: Human apo B-100 gene resides in the p23-pter region of chromosome 2. Biochem Biophys Res Commun 1985; 131: 1003-1012.
71. Law SW, Grant SM, Higuchi K, Hospattankar A, Lackner K, Lee N, Brewer HBJ: Human liver apolipoprotein B-100 cDNA: Complete nucleic acid and derived amino acid sequence. Proc Natl Acad Sci USA 1986; 83: 8142-8146.
72. Leren TP, Rødningen OK, Tonstad S, Røsby O, Urdal P, Ose L: Identification of the apo B-3500 mutation in the Norwegian population. Scand J Clin Invest 1995; 55: 217-221.
73. Lindgren V, Luskey KL, Russel DW, Francke U: Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. Proc Natl Acad Sci USA 1985; 82: 8567-8571.
74. Ludwig EH, McCarthy BJ: Haplotype analysis of the human apolipoprotein B mutation associated with familial defective apolipoprotein B-100. Am J Hum Gen 1990; 47: 712-720.
75. Lund-Katz S, Innerarity TL, Arnold KS, Curtiss LK, Philips MC: 13C NMR evidence that substitution of glutamine for arginine 3500 in familial defective apolipoprotein B-100 disrupts the conformation of the receptor-binding domain. J Biol Chem 1991; 266: 2701-2704.
76. Maher VMG, Gallagher JJ, Thompson GR, Myant NB: Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100. Atheroslerosis 1991; 91: 73-76.
77. Maher VMG, Gallagher JJ, Myant NB: The binding of very low density lipoprotein remnants to the low density lipoprotein receptor in familial defective apolipoprotein B-100. Atheroslerosis 1993; 102: 51-61.
78. Mamotte CDS, van Bockxmeer FM: A robust strategy for screening and confirmation of familial defective apolipoprotein B-100. Clin Chem 1993; 39: 118-121.
79. Mamotte CDS, Sturm M, Foo JI, van Bockxmeer FM, Taylor RR: Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding. Atherosclerosis 1996; 125: 103-110.
80. Manke C, Schuster H, Keller C, Wolfram G: The effect of the apolipoprotein E polymorphism on lipid levels in patients with familial defective apolipoprotein B-100. Clin Invest 1993; 71: 277-280.
81. Marian AJ, Roberts R: Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995; 92: 1336-1347.
82. Maron BJ, Roberts WC, Epstein SE: Sudden death in hypertrophic cardiomyopathy: a profile in 78 patients. Circulation 1982; 65: 1388-1394.
83. Maron BJ, Nichols PF, Pickle LW, Wesley YE, Mulvihill JJ: Patterns of inheritance in hypertrophic cardiomyopathy. Assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 1984; 53: 1087-1094.
84. März W, Ruzicka C, Pohl T, Usadel KH, Gross W: Familial defective apolipoprotein B-100: mild hypercholesterolaemia without atherosclerosis in a homozygous patient. Lancet 1992; 340: 1362.
85. März W, Baumstark MW, Scharnagl H, Ruzicka V, Buxbaum S, Herwig J, Pohl T, Russ A, Schaaf L, Berg A, Böhles H-J, Usadel KH, Gross W: Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patient with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. J Clin Invest 1993; 92: 2922-2933.
86. Mendel CM: A novel assay for comparing affinity constants of ligands with small differences in affinity: application to low-density lipoproteins. Analyt Biochem 1994; 216: 328-334.
87. Milne R, Théolis RJ, Maurice R, Pease RJ, Weech PK, Rassart E, Fruchart JC, Scott J, Marcel YL: The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem 1989; 264: 19754-19760.
88. Miserez AR, Laager R, Chiodetti N, Keller U: High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 1994; 35: 574-583.
89. Miserez AR, Keller U: Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 1719-1729.
90. Morrisett JD, Guyton TR, Gaubatz JW, Gotto AM: Lipoprotein(a): structure, metabolism and epidemiology, in Gotto AM (ed): Plasma Lipoproteins. Amsterdam, Elsevier Science Publishers, 1987, pp 129-152.
91. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH, Keating MT, MacCluer JW, Timothy KW: ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-2934.
92. Motti C, Funke H, Rust S, Dergunov A, Assmann G: Using mutagenic polymerase chain reaction primers to detect carriers of familial defective apolipoprotein B-100. Clin Chem 1991; 37: 1762-1766.
93. Myant NB, Gallagher JJ, Knight BL, McCarthy SN, Frostegaard J, Nilsson J, Hamsten A, Talmud P, Humphries SE: Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arterioscler Thromb 1991; 11: 691-703.
94. Myant NB: Familial defective apolipoprotein B-100: a review, including comparisons with familial hypercholesterolemia. Atheroslerosis 1993; 104: 1-18.
95. Neaton JD, Blackburn H, Jacobs D: Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490-1500.
96. Nohara A, Yagi K, Inazu A, Kajinami K, Koizumi J, Mabuchi H: Absence of familial defective apolipoprotein B-100 in Japanese patients with familial hypercholesterolaemia. Lancet 1995; 345: 1438.
97. Pedersen JC, Berg K: Interaction between low density lipoprotein receptor (LDLR) and apolipoprotein E (apoE) alleles contributes to normal variation in lipid levels. Clin Genet 1989; 35: 331-337.
98. Poledne R, Pisa Z, Berg K: Normal genetic variation at the low density lipoprotein receptor (LDLR) locus influences cholesterol levels in children. Clin Genet 1993; 43: 122-126.
99. Pullinger CR, Hennessy LK, Chatterton JE, Liu W, Love JA, Mendel CM, Frost PH, Malloy MJ, Schumaker VN, Kane JP: Familial ligand-defective apolipoprotein B: identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 1995; 95: 225-1234.
100. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D: Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331.
101. Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Grossman M, Wilson JM, Brewer HB Jr.: The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95: 1403-1408.
102. Rall SC, Mahley RW: The role of apolipoprotein E genetic variants in lipoprotein disorders. J Int Med 1992; 231: 653-659.
103. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
104. Rauh G, Keller C, Kormann B, Spengel F, Schuster H, Wolfram G, Zöllner N: Familial defective apolipoprotein B-100: clinical characteristics of 54 cases. Atheroslerosis 1992; 92: 233-241.
105. Rauh G, Keller C, Schuster H, Wolfram G, Zöllner N: Familial defective apolipoprotein B-100: a common cause of primary hypercholesterolemia. Clin Invest 1992; 70: 77-84.
106. Rauh G, Schuster H, Schewe CK, Stratmann G, Keller C, Wolfram G, Zöllner N: Independent mutation of arginine3500-glutamine associated with familial defective apolipoprotein B-100. J Lipid Res 1993; 34: 799-805.
107. Rhoads GG, Dahlen G, Berg HK, Morton NE, Dannenberg AL: Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256: 2540-2544.
108. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM: Multiple mechanisms in the long-QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996; 94: 1996-2012.
109. Romano C, Gemme G, Pongigilione R: Aritmie cardiache rare in eta' pediatrica. Clin Pediatr 1963; 45: 656-683.
110. Ruzicka V, März W, Russ A, Gross W: Apolipoprotein B (Arg3500-Gln) allele specific polymerase chain reaction: large-scale screening of pooled blood samples. J Lipid Res 1992; 33: 1563-1567.
111. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol And Recurrent Events Trial investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
112. Schmidt EB, Illingworth DR, Bacon S, Mahley RW, Weisgraber KH: Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100. Atheroslerosis 1993; 98: 213-217.
113. Schmidt EB, Illingworth DR, Bacon S, Russell SJ, Thatcher SR, Mahley RW, Weisgraber KH: Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100. Metabolism 1993; 42: 137-139.
114. Schmilz G, Brüning T, Kovacs E, Barlage S: Fluorescence flow cytometry of human leukocytes in the detection of LDL receptor defects in differential diagnosis of hypercholesterolemia. Arterioscler Thromb 1993; 13: 1053-1065.
115. Schuster H, Humphries S, Rauh G, Held C, Keller C, Wolfram G, Zöllner N: Association of DNA-haplotypes in the human LDL-receptorgene with normal serum cholesterol levels. Clin Genet 1990; 38: 401-409.
116. Schuster H, Rauh G, Kormann B, Hepp T, Humphries S, Keller C, Wolfram G, Zöllner N: Familial defective apolipoprotein B-100: comparison with familial hypercholesterolemia in 18 cases detected in Munich. Arterioscler Thromb 1990; 10: 577-581.
117. Schuster H, Rauh G, Müller S, Keller C, Wolfram G, Zöllner N: Allele-specific and asymmetric polymerase chain reaction amplification in combination: a one step polymerase chain reaction protocol for rapid diagnosis of familial defective apolipoprotein B-100. Analyt Biochem 1992; 204: 22-25.
118. Schwartz EI, Shevtsov SP, Kuchinski AP, Kovalev YR Plutaiov OV, Berlin YA: Approach to identification of a point mutation in apo B100 gene by means of a PCR-mediated site-directed mutagenesis, Nucl Acids Res 1991; 19: 3752.
119. + channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation 1995; 92: 3381-3386.
120. Seed M, Hopplicher F, Reavely D, McCarthy S, Boerwinkle E, Thompson GR, Utermann G: Relation of serum lipoprotein(a) concentration and lipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494-1499.
121. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
122. Sniderman A, Shapiro S, Marpole D, Malcolm I, Sinner B, Kwiterovich PO: Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol content in human plasma low density lipoprotein). Proc Natl Acad Sci USA 1980; 77: 604-608.
123. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ: Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989; 86: 587-591.
124. Soutar AK, McCarthy SN, Seed M, Knight BL: Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma and low density lipoprotein (LDL) receptor function in a large kindred with familial hypercholesterolemia due to the pro664-Ieu mutation in the LDL-receptor gene. J Clin Invest 1991; 88: 483-492.
125. Teare D: Asymetrical hypertrophy of the heart in young adults. Br Heart J 1958; 20: 1-18.
126. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, Seidman CE: Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994; 77: 701-712.
127. Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, Seed M, Hamsten A, Humphries SE, Myant NB: Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics often cases. Atheroslerosis 1990; 80: 235-242.
128. Tybjaerg-Hansen A, Humphries SE: Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atheroslerosis 1992; 96: 91-107.
129. van den Broek AJCM, Hollaar L, Schaefer HIMB, van der Laarse A, Schuster H, Defesche JC, Kastelein JJP, van't Hooft FM: Screening for familial defective apolipoprotein B-100 with improved U937 monocyte proliferation assay. Clin Chem 1994; 40: 395-399.
130. Vega GL, Grundy SM: In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 1986; 78: 1410-1414.
131. Vessby B, Kostner G, Lithell H, Thomis J: Diverging effects of chofestyramine on apolipoprotein B and lipoprotein Lp(a). Atheroslerosis 1982; 44: 61-71.
132. Ward OC: New familial cardiac syndrome in children. J Irish Med Assoc 1964; 54: 103-106.
133. Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna WJ, Maron BJ, Seidman JG, Seidman CE: Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995; 11: 434-437.
134. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG, Seidman CE: Mutations in the genes for cardiac troponin T and alfa-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995; 332: 1058-1064.
135. Wenham PR, Newton CR, Houlston RS, Price WH: Rapid diagnosis of familial detective apolipoprotein B-100 by amplification refractory mutation system. Clin Chem 1991; 37: 1983-1987.
136. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-1342.
137. Wicklund O, Angelin B, Oloffson S, Erikson M, Fager G, Berglund L, Bondjers G: Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; ii: 1360-1363.
138. Young SG, Bertics SJ, Curtiss LK, Casal DC, Witztum JL: Monoclonal anti-body MB 19 detecs genetic polymorphism in human apolipoprotein B. Proc Natl Acad Sci USA 1986; 83: 1101-1105.
139. Young SG: Recent progress in understanding apolipoprotein B. Circulation 1990; 82: 1574-1594.